Dyne Therapeutics (DYN) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 245.2% versus a gain of 14.5%. Dyne Therapeutics is the larger company by market cap ($2.98 billion vs $2.63 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYN | MBX |
|---|---|---|
| Share price | $15.97 | $54.54 |
| Market cap | $2.98B | $2.63B |
| 1-day change | +3.70% | -4.18% |
| YTD return | -18.35% | +72.92% |
| 1-year return | +14.48% | +245.19% |
| 5-year return | +7.33% | — |
| EPS (TTM) | $-3.30 | $-2.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-446.21M | $-87.00M |
| 52-week high | $27.31 | $72.64 |
| 52-week low | $13.73 | $12.94 |
| Distance from 52-week high | -41.51% | -24.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +125.42% | +72.90% |
| Average volume | 2.77M | 556.72K |
| Shares outstanding | 186.75M | 48.16M |
| Employees | 289 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed DYN by 230.7 percentage points over the past year.
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
DYN vs MBX FAQ
Which is bigger, Dyne Therapeutics or MBX Biosciences?
Dyne Therapeutics (DYN) is larger, with a market capitalization of $2.98B compared with $2.63B for MBX Biosciences (MBX).
Which stock has performed better over the past year, DYN or MBX?
MBX returned +245.19% over the past 12 months, compared with +14.48% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are Dyne Therapeutics and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.